» Articles » PMID: 36034842

Dihydroartemisinin Remodels Macrophage into an M1 Phenotype Ferroptosis-mediated DNA Damage

Overview
Journal Front Pharmacol
Date 2022 Aug 29
PMID 36034842
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer recruits tumor-associated macrophages (TAMs) massively, whose predominantly pro-tumor M2 phenotype leads to immunosuppression. Dihydroartemisinin (DHA) has been proven to remodel TAM into an anti-tumor M1 phenotype at certain concentrations in the present study, which was hypothesized to facilitate anti-lung cancer immunotherapy. However, how DHA remodels the TAM phenotype has not yet been uncovered. Our previous work revealed that DHA could trigger ferroptosis in lung cancer cells, which may also be observed in TAM thereupon. Sequentially, in the current study, DHA was found to remodel TAM into the M1 phenotype and . Simultaneously, DHA was observed to trigger ferroptosis in TAM and cause the DNA damage response and NF-κB activation. Conversely, the DHA-induced DNA damage response and NF-κB activation in TAM were attenuated after the inhibition of ferroptosis in TAM using an inhibitor of ferroptosis. Importantly, a ferroptosis inhibitor could also abolish the DHA-induced phenotypic remodeling of TAM toward the M1 phenotype. In a nutshell, this work demonstrates that DHA-triggered ferroptosis of TAM results in DNA damage, which could activate downstream NF-κB to remodel TAM into an M1 phenotype, providing a novel strategy for anti-lung cancer immunotherapy. This study offers a novel strategy and theoretical basis for the use of traditional Chinese medicine monomers to regulate the anti-tumor immune response, as well as a new therapeutic target for TAM phenotype remodeling.

Citing Articles

Regulation of Ferroptosis in Cancer and Immune Cells.

Jang N, Kim I, Jung D, Chung Y, Kang Y Immune Netw. 2025; 25(1):e6.

PMID: 40078787 PMC: 11896659. DOI: 10.4110/in.2025.25.e6.


-Derived β-Glucan as a Novel Modulator of Tumor Microenvironment: Targeting Macrophage Polarization and Inducing Ferroptosis in Lung Cancer.

He X, Ran Q, Li X, Xiong A, Zhang L, Jiang M J Inflamm Res. 2024; 17:10479-10494.

PMID: 39659749 PMC: 11630740. DOI: 10.2147/JIR.S489191.


Interactions between ferroptosis and tumour development mechanisms: Implications for gynaecological cancer therapy (Review).

Wu P, Chen J, Li H, Lu H, Li Y, Zhang J Oncol Rep. 2024; 53(2).

PMID: 39635847 PMC: 11638741. DOI: 10.3892/or.2024.8851.


Ferroptosis and the tumor microenvironment.

Cui K, Wang K, Huang Z J Exp Clin Cancer Res. 2024; 43(1):315.

PMID: 39614322 PMC: 11607824. DOI: 10.1186/s13046-024-03235-0.


Interaction between macrophages and ferroptosis: Metabolism, function, and diseases.

Jiang Q, Wan R, Jiang J, Li T, Li Y, Yu S Chin Med J (Engl). 2024; .

PMID: 39245648 PMC: 11882282. DOI: 10.1097/CM9.0000000000003189.


References
1.
Liu J, Tang W, Fu M, Gong X, Kong L, Yao X . Development of R modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artif Cells Nanomed Biotechnol. 2019; 47(1):1947-1960. DOI: 10.1080/21691401.2019.1615932. View

2.
Han N, Li L, Peng X, Ma Q, Yang Z, Wang X . Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS. Eur J Pharmacol. 2022; 919:174797. DOI: 10.1016/j.ejphar.2022.174797. View

3.
Zhou Y, Que K, Zhang Z, Yi Z, Zhao P, You Y . Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway. Cancer Med. 2018; 7(8):4012-4022. PMC: 6089144. DOI: 10.1002/cam4.1670. View

4.
Lavin Y, Kobayashi S, Leader A, Amir E, Elefant N, Bigenwald C . Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017; 169(4):750-765.e17. PMC: 5737939. DOI: 10.1016/j.cell.2017.04.014. View

5.
Sarode P, Zheng X, Giotopoulou G, Weigert A, Kuenne C, Gunther S . Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. Sci Adv. 2020; 6(23):eaaz6105. PMC: 7274802. DOI: 10.1126/sciadv.aaz6105. View